Finance entity
All 1 tracked stories fall under one category: regulation. Teva Pharmaceutical Industries is most often covered alongside Corcept Therapeutics Incorporated, which appears in 1 of these 1 story. Each story carries 10 original sources on average, compared with 2.4 for the broader beat in this window.
Last mentioned: Aug 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Teva Pharmaceutical Industries is most often covered alongside Corcept Therapeutics Incorporated, which appears in 1 of these 1 story. Each story carries 10 original sources on average, compared with 2.4 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 6.2. Teva Pharmaceutical Industries appears in 1 tracked Finance story from February 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 85 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Teva Pharmaceutical Industries. Shared-story counts are live from our verified record — not editorial picks.
Lawsuit Announced
Rosen Law Firm announces the filing of the class action lawsuit and lead plaintiff opportunity.
Teva Legal Victory
Teva Pharmaceutical Industries wins an appeals court ruling over generic versions of Corcept's Korlym.
Class Period Ends
The cutoff date for the class action, often coinciding with a corrective disclosure.
Class Period Begins
The start date for the alleged period of securities fraud and misleading statements.
Corcept Therapeutics (NASDAQ: CORT) is the target of a class action lawsuit alleging securities fraud during a critical 14-month period of operational and legal shifts. The Rosen Law Firm is seeking lead plaintiffs for a class period that concluded in late 2025, amid intensifying pressure on the company's core product patents.
Teva Pharmaceutical Industries is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
